Aethlon Merges with North Immunology to form Nasdaq-listed NRTX with $180M funding
Aethlon Medical announces an all-stock merger with North Immunology, creating a combined company to trade as NRTX on Nasdaq Capital Market. A $180 million private placement backs the deal, supporting NOR-101 development and Hemopurifier monetization through contingent rights. Close is targeted for Q1 2027, subject to approvals; the deal pledges substantial equity value and a clear pipeline plan, but triggers meaningful dilution for existing AEMD holders.
View signal analysis